Jefferies downgraded Apple Inc (NASDAQ:AAPL, ETR:APC). (AAPL) to 'hold' and cut its price target to $212.92, citing unrealistic iPhone 16 expectations and the stock’s near-record valuation.
Digging deeper, the US bank warned that excitement over Apple’s next iPhone cycles, particularly the iPhone 16 and upcoming iPhone 17, is premature.
Lower interest rates might prove to be a benefit to the wealth platforms, suggest analysts at broker Panmure Liberum
The broker acknowledges that retained income from investors’ cash balances has been a boon to various businesses over the last two years
Sirius Real Estate Limited (LSE:SRE, JSE:SRE, OTC:SRRLF) has had a 'buy' rating reaffirmed by two brokers after today's pre-interim results trading update, which reiterated business was in line with management expectations.
Panmure Liberum said that consensus forecasts are for full-year funds from operations (FFO) to be around €123 million and 8.4c, which is slightly above its forecast for €122 million and 8.22c.
Britain's housing market appears to be “firmly back on track” following news that prices in September moved within touching distance of record highs.
Halifax reported earlier that prices ticked up by 4.7% in September to £293,399, a third successive month of growth.
Jefferies has downgraded its rating on Novo Nordisk (NYSE:NVO) to "underperform" and cut its price target to DKK 575, down from the previous DKK 782.90.
The downgrade comes amid concerns over the supply of the Danish drugs giant's weight-loss drug, Wegovy, particularly in the United States, where prescriptions for the 0.25 mg starter dose have dropped significantly.
Experian (LSE:EXPN) has been upgraded by Deutsche Bank to 'buy' from 'hold' on the potential for strong future growth driven by strategic investments in key platforms.
The share price target was hiked by 1,200p to 4,750p in the note, with Deutsche citing the credit checking agency's recent focus on hyperscaling — a phase of rapid business growth — as the basis for the upgrade.
Futura Medical PLC (AIM:FUM, OTC:FAMDF) shares rose in early trading after the company secured a $5 million milestone payment following the US launch of its erectile dysfunction gel, Eroxon.
The payment was triggered as distribution partner Haleon began fulfilling online pre-orders and making the product available in US retail stores.